SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lasa Supergenerics - Quaterly Results

07 Feb 2022 Evaluate
The sales moved down -70.85% to Rs. 157.37 millions for the December 2021 quarter as compared to Rs. 539.87 millions during the corresponding quarter last year.The Net Loss for the quarter ended December 2021 is Rs. -47.14 millions as compared to Net Profit of Rs. 65.56 millions of corresponding quarter ended December 2020Operating profit Margin for the quarter ended December 2021 slipped to -11.69% as compared to 127.70% of corresponding quarter ended December 2020


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 157.37 539.87 -70.85 859.14 1632.78 -47.38 2023.80 1672.71 20.99
Other Income 0.13 0.15 -13.33 0.49 0.53 -7.55 0.58 2.32 -75.00
PBIDT -11.69 127.70 -109.15 47.49 381.88 -87.56 472.79 301.80 56.66
Interest 0.07 0.76 -90.79 0.33 19.30 -98.29 19.63 81.04 -75.78
PBDT -11.76 126.94 -109.26 -71.88 362.58 -119.82 453.16 220.76 105.27
Depreciation 35.91 40.91 -12.22 105.16 118.84 -11.51 158.24 173.39 -8.74
PBT -47.67 86.03 -155.41 -177.04 243.74 -172.63 294.92 47.37 522.59
TAX -0.53 20.47 -102.59 -0.53 53.96 -100.98 67.14 11.08 505.96
Deferred Tax -0.53 14.00 -103.79 -4.74 56.57 -108.38 56.47 -1.68 -3461.31
PAT -47.14 65.56 -171.90 -176.51 189.78 -193.01 227.78 36.29 527.67
Equity 406.73 406.73 0.00 406.73 406.73 0.00 406.73 406.73 0.00
PBIDTM(%) -7.43 23.65 -131.40 5.53 23.39 -76.37 23.36 18.04 29.48

Lasa Supergenerics Share Price

8.47 0.33 (4.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×